07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Merck KGaA, Ono Pharmaceutical deal

Merck is returning rights to Ono for ceralifimod ( ONO-4641), a sphingosine 1-phosphate (S1P) receptor agonist in development for multiple sclerosis (MS). Merck’s Merck Serono S.A. unit has exclusive rights outside of Japan,...
00:50 , Jun 18, 2014 |  BC Extra  |  Company News

Merck returning S1P receptor agonist to Ono

Merck KGaA (Xetra:MRK) is returning rights to Ono Pharmaceutical Co. Ltd. (Tokyo:4528) for ceralifimod ( ONO-4641), a sphingosine 1-phosphate (S1P) receptor agonist in development for multiple sclerosis (MS). Merck's Merck Serono S.A. unit has exclusive...
07:00 , May 28, 2012 |  BioCentury  |  Product Development

Devil is in the dosing

Data released in April suggest the theory behind second-generation sphingosine 1-phosphate receptor agonists in development for multiple sclerosis was wrong. However, two companies are finding that improved pharmacokinetics and/or dose titration could achieve the original...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

ONO-4641: Phase II data

The double-blind, international Phase II DreaMS trial in 407 patients aged 18-55 with RRMS showed that once-daily 0.05, 0.1 and 0.15 mg oral ONO-4641 all met the primary endpoint of reducing the number of gadolinium-enhancing...
01:08 , Apr 18, 2012 |  BC Extra  |  Clinical News

Ono's S1P receptor agonist meets RRMS endpoint

Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) said once-daily 0.05, 0.1 and 0.15 mg doses of oral ONO-4641 all met the primary endpoint of reducing the number of gadolinium-enhancing lesions in four-week intervals for 26 weeks...
07:00 , Mar 19, 2012 |  BioCentury  |  Strategy

Remaking Merck Serono

Five years after spending $13.2 billion to acquire Serono S.A. as a growth platform, Merck KGaA finds itself with much higher pharmaceutical sales than it could have achieved on its own, but no obvious way...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Merck KGaA, Ono Pharmaceutical deal

Ono granted Merck's Merck Serono S.A. division exclusive rights outside of Japan, Korea and Taiwan to develop and commercialize multiple sclerosis (MS) compound ONO-4641. The sphingosine 1-phosphate (S1P) receptor agonist is in...
00:33 , Oct 5, 2011 |  BC Extra  |  Company News

Merck Serono in-licenses Ono's S1P receptor agonist

Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) granted Merck Serono exclusive rights outside of Japan, Korea and Taiwan to develop and commercialize multiple sclerosis (MS) compound ONO-4641. The sphingosine 1-phosphate (S1P) receptor agonist is in Phase...